Advertisement

Topics

This Antibody Could Boost Checkpoint Inhibitors in Treating Colorectal Cancer

06:55 EDT 17 May 2018 | Labiotech.eu

Innate Pharma has preliminary Phase I data showing its monoclonal antibody could treat colorectal cancer that is unresponsive to PD-1/L1 checkpoint inhibitors. French biotech Innate Pharma has obtained promising Phase I data for its monoclonal antibody monalizumab in treating colorectal cancer. ...

This awesome article This Antibody Could Boost Checkpoint Inhibitors in Treating Colorectal Cancer appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: This Antibody Could Boost Checkpoint Inhibitors in Treating Colorectal Cancer

NEXT ARTICLE

More From BioPortfolio on "This Antibody Could Boost Checkpoint Inhibitors in Treating Colorectal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...